Clinical Report: Laser-Titratable Shunt Achieves IOP Reduction at 12 Months

Overview

The Calibreye system demonstrates a significant intraocular pressure (IOP) reduction of 35% and medication savings at 12 months post-implantation. This laser-adjustable aqueous shunt allows for safe modulation of outflow resistance, offering a novel approach to glaucoma management.

Background

Managing intraocular pressure (IOP) is crucial in glaucoma treatment to prevent vision loss. Traditional drainage implants have limitations, such as fixed outflow resistance and potential complications. The ability to adjust outflow postoperatively could enhance patient outcomes. The Calibreye system represents an innovative solution that may improve IOP control while reducing reliance on medications.

Data Highlights

Key Findings

• The Calibreye system allows for adjustable outflow resistance post-implantation.
• At 12 months, mean IOP was reduced by 35% from baseline.
• 81% of implanted eyes were set at the device's lowest resistance level.
• 93.5% of patients were medication-free or using fewer medications than at baseline.
• No intraprocedural adverse events were reported during the study.

Clinical Implications

The ability to adjust IOP postoperatively with the Calibreye system may enhance individualized patient care in glaucoma management. Clinicians can tailor treatment based on real-time IOP measurements, potentially reducing the risk of hypotony and improving long-term outcomes by making timely adjustments.

Conclusion

The Calibreye Titratable Glaucoma Therapy Surgical System shows promise in achieving significant IOP reduction and medication savings, warranting further investigation in larger studies, particularly focusing on long-term safety and effectiveness.

References

1. Glaucoma Physician, 2026 -- Laser-Titratable Shunt Achieves IOP Reduction at 12 Months
2. Glaucoma Physician, 2025 -- Laser-Titratable Shunt Shows Promise in Feasibility Study
3. Glaucoma Physician, 2026 -- Diurnal IOP Fluctuation Drops After SLT, Study Finds
4. Glaucoma Physician, 2023 -- Fixed High-energy SLT Superior to Standard Titrated Protocol for IOP Lowering
5. Primary Open-Angle Glaucoma Preferred Practice Pattern® - PubMed
6. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 5 Years of Follow-up - PubMed
7. Glaucoma Physician — Diurnal IOP Fluctuation Drops After SLT, Study Finds
8. Primary Open-Angle Glaucoma Preferred Practice Pattern® - PubMed
9. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 5 Years of Follow-up - PubMed
10. Laser-Titratable Shunt Achieves IOP Reduction at 12 Months | Glaucoma Physician